Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01805791
Other study ID # HMPL-004-03
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 2013
Est. completion date October 2014

Study information

Verified date July 2018
Source Hutchison Medipharma Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a concomitant medication.

The objective is to evaluate the efficacy and safety of HMPL-004 with mesalamine (mesalamine treatment failures). Efficacy will be measured by a comparison of the proportion of patients in each treatment group attaining clinical remission at Week 8 as compared to placebo.


Description:

This Phase III study of HMPL-004 was to enroll approximately 420 subjects with active mild to moderate ulcerative colitis (UC; modified Mayo Score 4-10 and endoscopy score of 2-3). The trial included male and female subjects aged 18 or older. Subjects were currently receiving ≥2.4 g/day mesalamine or equivalent, provided they had taken 5-aminosalicylate (ASA; i.e., mesalamine) at a dose ≥2.4 g/day for at least 6 weeks prior to randomization and were on a stable dosage for at least 2 weeks prior to entering the screening phase of the study.

Qualifying subjects who entered into this study received 3 daily doses of oral HMPL 004 tablets or placebo for 56 days (8 weeks). There were 3 arms in this study consisting of placebo, HMPL-004 600 mg three times a day (TID) or 800 mg TID. Approximately 420 subjects were to be randomized 1:1:1 to one of these 3 arms, stratified by country/region in up to 150 clinical centers in North America, Europe, and Asia.


Recruitment information / eligibility

Status Terminated
Enrollment 201
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients must be currently receiving mesalamine = 2.4 g/day (or the equivalent) for at least 6 weeks prior to randomization and on a stable dosage for at least 2 weeks prior to entering the screening phase of the study to ensure a stable dose is established at least 2 weeks prior to the endoscopic procedures.

- Have active mild to moderate ulcerative colitis defined by a modified Mayo Score 4-10, and with endoscopy score activity of 2-3 points confirmed by centrally read colonoscopy (within 2 weeks prior to randomization.

- Minimum modified Mayo endoscopy score of >2 at the time of study colonoscopy.

- Age = 18 years.

- Patients have no prior exposure to HMPL-004.

- Have adequate renal, hepatic and bone marrow function (see exclusion criteria).

- All fertile male and female subjects must agree to use one of the following types of contraception: abstinence, intrauterine device, implantable progesterone device, and progesterone intramuscular injection, oral contraceptive which has been started at least one month prior to visit one and continues for the duration of the trial, contraceptive patch, or condom with spermicide.

- Show evidence of a personally signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial

Exclusion Criteria:

1. Subjects with intolerance or adverse reactions to mesalamine (or equivalent medications).

2. Diagnosed with Crohn's Disease or with lesions such as fistulas or granulomas on biopsy noted either in history or at baseline endoscope, which would be suspicious for Crohn's disease, or with a diagnosis of indeterminate colitis. Subjects with Primary Sclerosing Cholangitis (PSC) are excluded..

3. Severe disease with an ulcerative colitis modified Mayo Clinic score above 10 points at baseline.

4. Positive stool test for pathogens for sample taken within the previous 2 weeks prior to study entry.

5. Active Clostridium difficile (C. diff) infection.

6. Use of Inflammatory Bowel Disease related herbal supplements including but not limited to supplements containing andrographis and probiotics two weeks prior to study entry or during the study.

7. Toxic megacolon or toxic colitis.

8. Probable requirement for intestinal surgery within 12 weeks after the start of study medication.

9. Receiving oral or rectal steroids within 1 month prior to study entry.

10. Receiving rectal mesalamine within one week prior to study entry.

11. Receiving azathioprine, 6-mercaptopurine, methotrexate, tacrolimus, cyclosporine, or other immunosuppressive therapy at the time of screening or within the preceding 6 weeks.

12. Receiving anti-tumor necrosis factor-a agents such as infliximab, adalimumab, golimumab, or certolizumab pegol at the time of screening or within the preceding 8 weeks.

13. Receiving other investigational drugs or biologics within 1 month or five half lives.

14. Receiving antibiotics within 2 weeks of study entry.

15. Hemoglobin concentration < 9 g/dl.

16. White blood cell count (WBC) below 3,000/cmm, or platelets below 100,000/cmm.

17. Serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase >2.5 upper limit of normal.

18. Serum creatinine >1.5 times upper limit of normal.

19. Significant concurrent medical diseases including: active peptic ulcer disease; uncompensated congestive heart disease; myocardial infarction within the last 12 months; unstable angina pectoris; uncontrolled hypertension; pulmonary disease requiring oxygen therapy.

20. Chronic Hepatitis B or any history of Hepatitis C.

21. Previous colonic surgery except for simple polypectomy or appendectomy. .

22. History of cancer within the last 5 years other than resected cutaneous basal and squamous cell carcinomas, and in situ cervical cancer.

23. Patients with a history of or concurrent colonic dysplasia associated with UC, except those with completely excised sporadic colorectal polyps.

24. Women who are pregnant or breast feeding.

25. Patients known to be seropositive for HIV, or who have had an AIDS defining illness, or a known immunodeficiency disorder.

26. Patients with a history of tuberculosis or exposure to tuberculosis, or a history of a chest X-ray suspicious for tuberculosis, unless confirmed to be purified protein derivative (PPD) skin test negative or latent tuberculosis that has been previously treated.

27. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.

28. Known allergy to plants of the Acanthaceae family.

29. Unwillingness to participate in the study.

30. Any underlying medical condition that in the Investigator's opinion will make the administration of study drug hazardous to the patient or would obscure the interpretation of adverse events.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HMPL-004 1800 mg/day
Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
Placebo
Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
HMPL-004 2400 mg/day
Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).

Locations

Country Name City State
United States Clinical Research Management, Inc Agawam Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects With a Clinical Remission at Week 8 Clinical remission was defined as a total Mayo Score of =2 points with no individual sub-score >1 point and rectal bleeding score = 0. 8 weeks
Secondary The Proportion of Subjects With Clinical Response at Week 8 Clinical response was defined as a decrease in a modified Mayo Score from baseline by =3 points and =30% decrease in the modified Mayo Score, along with either a decrease in the rectal bleeding score =1 or an absolute rectal bleeding score =1. 8 weeks
Secondary The Proportion of Subjects With Mucosal Healing at Week 8 Mucosal healing was defined as having normal or inactive disease using a modified Mayo Score to determine if the decrease in the modified Mayo endoscopy sub-score from baseline was =1 in at least 1 segment and had an absolute score =1 in all segments. 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2